Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD's The Liver Meeting® 2023 -November 10, 2023 at 08:02 am EST
Vir Biotechnology, Inc. today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 and VIR-2218 could have for chronic...
Source: marketscreener.com